Kabra Drugs Limited

BSE:524322 Stock Report

Market Cap: ₹101.4m

Kabra Drugs Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Nanjappan Aravind

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.5yrs
Board average tenure2.7yrs

Recent management updates

Recent updates

CEO

Nanjappan Aravind (55 yo)

less than a year

Tenure

Mr. Nanjappan Aravind, B.E. has been Additional Director of Kabra Drugs Limited since August 14, 2024. He has been the Chairman and Managing Director of Crazy Infra & Infomedia Limited (formerly known as C...

Leadership Team

NamePositionTenureCompensationOwnership
Monika Nishant Sanwal
Company Secretary & Compliance Officer2.6yrs₹113.00kno data
Nanjappan Aravind
MD & Directorless than a yearno datano data
Bangalore Venkatakrishnappa Kumar
Whole Time Director & CFO5.1yrsno datano data
Kuniamuthur Anand
Executive Directorless than a yearno data6.53%
₹ 6.6m

1.5yrs

Average Tenure

Experienced Management: 524322's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Nanjappan Aravind
MD & Directorless than a yearno datano data
Bangalore Venkatakrishnappa Kumar
Whole Time Director & CFO5.1yrsno datano data
Kuniamuthur Anand
Executive Director2.7yrsno data6.53%
₹ 6.6m
Anitha Anand
Independent Director2.6yrsno datano data
Ananthkumar Shilpa
Independent Woman Director5yrsno datano data

2.7yrs

Average Tenure

Experienced Board: 524322's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 06:54
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kabra Drugs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution